Is one better than the other?

ACHIEVE-3 reported greater weight reduction with orforglipron in adults with insufficiently controlled type 2 diabetes. Beyond that, they differ most in dosing convenience.

What happens if oral semaglutide is taken with food?

Absorption falls. The SNAC mechanism depends on gastric conditions, which is why the dosing instructions exist.

Could a peptide ever be taken orally without an enhancer?

Not at this size and structure. The barriers are acid, proteases and permeability, and all three follow from the peptide backbone.

GLP-1 & Incretin Science

Oral Semaglutide vs Orforglipron

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Both are taken as tablets, but only oral semaglutide is a peptide. It reaches the circulation with the help of the absorption enhancer SNAC and requires a fasting window and a defined volume of water. Orforglipron has no peptide bonds, needs no enhancer, and can be taken at any time with no food or water conditions.

Key facts

Oral semaglutide: Peptide, requires SNAC enhancer
Orforglipron: Small molecule, no enhancer
Semaglutide dosing conditions: Fasting window, defined water volume
Orforglipron conditions: None — any time of day
Receptor site: Orthosteric vs transmembrane allosteric
ACHIEVE-3: Orforglipron > oral semaglutide in T2D

The same route, two completely different solutions

Getting a GLP-1 agonist into the bloodstream through the stomach has two possible answers. Protect a fragile peptide well enough that some of it survives, or design a molecule that was never fragile. Oral semaglutide took the first route; orforglipron took the second. Both produce tablets, and almost nothing else about them is comparable.

How SNAC works and what it costs

Salcaprozate sodium is co-formulated with oral semaglutide. It raises pH locally around the dissolving tablet, shielding the peptide from acid and pepsin, and transiently increases permeability of the gastric mucosa so a fraction of the dose crosses. The mechanism depends on conditions in the stomach, which is where the dosing instructions come from: an empty stomach, a small defined volume of water, and a wait before eating.

Why orforglipron has no such conditions

It contains no peptide bonds, so there is nothing for pepsin, trypsin or DPP-4 to cleave, and no reason to shield it. It was also designed from the start for permeability, with polar groups positioned to balance solubility against membrane crossing. Nothing about its absorption depends on gastric conditions, so there is nothing to instruct the patient about.

The receptor difference underneath

Oral semaglutide binds the GLP-1 receptor where the natural hormone does, across a broad extracellular surface. Orforglipron cannot — a small molecule has no way to cover that area — so it binds a hydrophobic pocket in the transmembrane domain and acts allosterically. Same receptor, same downstream signalling, entirely different point of contact.

Head to head

The ACHIEVE-3 study, reported in February 2026, found orforglipron produced greater weight reduction than oral semaglutide in adults with insufficiently controlled type 2 diabetes. That is a direct comparison of the two oral approaches in the same trial, which is more informative than comparing headline figures across separate studies.

Quick reference

	Oral semaglutide	Orforglipron
Molecule class	Peptide	Small molecule
Absorption enhancer	SNAC required	None
Food/water conditions	Yes — fasting window	None
Receptor site	Extracellular orthosteric	Transmembrane allosteric
Protease susceptible	Yes — hence SNAC	No
UK status	Authorised	Authorised 10 Aug 2026

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is one better than the other?: ACHIEVE-3 reported greater weight reduction with orforglipron in adults with insufficiently controlled type 2 diabetes. Beyond that, they differ most in dosing convenience.
What happens if oral semaglutide is taken with food?: Absorption falls. The SNAC mechanism depends on gastric conditions, which is why the dosing instructions exist.
Could a peptide ever be taken orally without an enhancer?: Not at this size and structure. The barriers are acid, proteases and permeability, and all three follow from the peptide backbone.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum